Clinical Study
Renal Transplantation in Hepatitis C Positive Patients: A Single Centre Experience
| Patients () | Group A () | Group B () | value |
| Study period | Jan 99–Dec 06 | Jan 98–Dec 06 | | Mean followup (years; range) | (3.8–11.8) | (4–12.6) | | Mean SCr (mg/dL) at | | | | 1 year | | | NS | 3 years | | | NS | 5 years | | | NS | 7 years | | | NS | 10 years | | | NS | Predominant biopsy findings—percentage | | Acute rejection episodes—percentage | | Bcell mediated | 8.3 () | 15.2 () | NS | Tcell mediated | 8.3 () | 17.7 () | 0.03 | Suspicious T/B | 9.8/0 (/0) | 20.2/5 (/4) | 0.024/0.022 | Acute CNI toxicity | 12.1 () | 19 () | NS | Recurrence | 1.5 () | 2.5 () | NS | Chronic rejections | | Bcell mediated | 3 () | 6.3 () | NS | Tcell mediated | 3.8 () | 11.4 () | 0.029 | IFTA | 8.3 () | 19 () | 0.018 | Chronic CNI toxicity | 9.1 () | 16.5 () | NS | Recurrence | 2.3 () (ATIN) | 3.8 ( (ATIN), (MPGN)) | NS | De novo nephropathy | 1 (MN) | 0 | NS | Chronic liver failure dueto reactivation | 22 () | 31 () | |
|
|
Abbreviations: CNI: calcineurin inhibitor; CGN: chronic glomerulonephritis; CsA: cyclosporin A; ELISA: enzyme linked immunoassay; ESRD: end-stage renal disease; G-CSF: granulocyte colony stimulating factor; HCV: hepatitis C virus; IFTA: unexplained interstitial fibrosis and tubular atrophy; LCM: lymphocyte cross-matching; PBSC: peripheral blood stem cells; POD: postoperative day; RTx: renal transplantation; SCr: serum creatinine; TIP: tolerance induction protocol.
|